TESARO (TSRO) Misses Q4 EPS by 30c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to TESARO (TSRO) Misses Q4 EPS by 30c

TESARO Announces Fourth-Quarter 2014 Operating Results

February 19, 2015 4:01 PM EST

Enrollment in niraparib NOVA non-gBRCA cohort on track to complete during Q1 2015 New QUADRA trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015 U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015 Cash and cash equivalents totaled approximately $257 Million as of December 31, 2014

WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today reported financial results for fourth-quarter and full-year 2014 and provided an update on the Company's... More